Sign In

A subscription to JoVE is required to view this content. Sign in or start your free trial.

In This Article

  • Summary
  • Abstract
  • Introduction
  • Protocol
  • Representative Results
  • Discussion
  • Acknowledgements
  • Materials
  • References
  • Reprints and Permissions

Summary

This protocol describes the generation of murine orthotopic bladder tumors in female C57BL/6J mice and the monitoring of tumor growth.

Abstract

This protocol describes the generation of bladder tumors in female C57BL/6J mice using the murine bladder cancer cell line MB49, which has been modified to secrete human Prostate Specific Antigen (PSA), and the procedure for the confirmation of tumor implantation. In brief, mice are anesthetized using injectable drugs and are made to lay in the dorsal position. Urine is vacated from the bladder and 50 µL of poly-L-lysine (PLL) is slowly instilled at a rate of 10 µL/20 s using a 24 G IV catheter. It is left in the bladder for 20 min by stoppering the catheter. The catheter is removed and PLL is vacated by gentle pressure on the bladder. This is followed by instillation of the murine bladder cancer cell line (1 x 105 cells/50 µL) at a rate of 10 µL/20 s. The catheter is stoppered to prevent premature evacuation. After 1 h, the mice are revived with a reversal drug, and the bladder is vacated. The slow instillation rate is important, as it reduces vesico-ureteral reflux, which can cause tumors to occur in the upper urinary tract and in the kidneys. The cell line should be well re-suspended to reduce clumping of cells, as this can lead to uneven tumor sizes after implantation.

This technique induces tumors with high efficiency. Tumor growth is monitored by urinary PSA secretion. PSA marker monitoring is more reliable than ultrasound or fluorescence imaging for the detection of the presence of tumors in the bladder. Tumors in mice generally reach a maximum size that negatively impacts health by about 3 - 4 weeks if left untreated. By monitoring tumor growth, it is possible to differentiate mice that were cured from those that were not successfully implanted with tumors. With only end-point analysis, the latter may be mistakenly assumed to have been cured by therapy.

Introduction

The goal of this method is to generate murine orthotopic bladder tumors and to monitor the implanted tumors as accurately as possible, so that mice without tumor implantation are not thought to have been cured at end-point analysis. Overall, the method shown will reduce the need for large numbers of mice for experimental analysis and ensure greater accuracy in determining therapeutic outcomes.

The development of an orthotopic model for cancer is important, as implanting tumor cells subcutaneously does not recapitulate the environment of the clinical disease or enable the development of therapeutic strategies. The architecture of the bladder....

Protocol

All animal work adhered to the Institutional Animal Care and Use Committee (IACUC) guidelines on animal use and handling (Protocol number 084/12) at the National University of Singapore.

1. Growing MB49-PSA Cells In Vitro and Measuring PSA Secretion

  1. Maintain murine bladder cancer cells MB49-PSA15 in complete Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mmol/L L-glutamine, and 0.05 mg/mL Penicillin-Strepto.......

Representative Results

PSA secretion from MB49 cells was found to vary with the growth media. MB49-PSA is grown in DMEM media because this results in increased PSA secretion (Figure 1A). In order to determine the sensitivity of the PSA ELISA and real-time PCR, different numbers of MB49-PSA-secreting cells were mixed with MB49 parental cells. PSA ELISA detects a minimum of 1 x 105 PSA-secreting cells/1 x 106 cells (Figure 1B), while real-time PCR analysis d.......

Discussion

The most critical steps in the protocol are 1) successfully maintaining the tumorigenicity of the cell line; 2) ensuring measurable PSA secretion before tumor cell implantation in mice; 3) generating a single-cell suspension for implantation so as to reduce variation in tumor size; and 4) instilling cells at a slow rate to prevent vesico-ureteral reflux, resulting in tumor cell implantation in the kidney.

After prolonged passage in vitro, MB49/MB49-PSA cells can lose their tumorigenic.......

Acknowledgements

This work was funded by a grant from the National Medical Research Council of Singapore (NMRC/CIRG/1335/2012) awarded to Professor Kesavan Esuvaranathan.

....

Materials

NameCompanyCatalog NumberComments
MB49-PSA cellsN/AN/Aref (Wu QH, 2004)
RPMI 1640 mediaHyCloneSH30027.01 
Dulbecco's Modified Eagle's Medium (DMEM) mediaBiowestL0102
Fetal Bovine Serum (FBS) South AmericanBiowestS1810
Fetal Bovine Serum (FBS) South American, PremiumBiowestS181B
Fetal Bovine Serum (FBS)HyCloneSH30088.03 
L-glutamineBiowestX0550
Penicillin-StreptomycinBiowestL0022
Hygromycin BInvitrogen10687-010
free PSA (Human) ELISA kitAbnovaKA0209
TRIzol Reagent for RNA extraction Ambion15596026
High Capacity cDNA Reverse Transcription Kit with RNase InhibitorApplied Biosystems4374967
TaqMan Universal PCR Master MixApplied Biosystems4304437
TaqMan Gene Expression Assay – Mouse ActbApplied Biosystems4331182Mm00607939_s1
TaqMan Gene Expression Assay – Human KLK3Applied Biosystems4331182Hs00426859_g1
C57BL/6J female miceIn Vivos4-6 wk old
Anesthesia (75mg/kg Ketamine and 1mg/kg Medetomidine)Local pharmacy
Reversal drug (1mg/kg Atipamezole)Local pharmacy
Ear punchElectron Microscopy Sciences72893-01
Hartmann's solution or Compound sodium lactateB Braun
Ophthalmic ointment - Duratears sterile ocular lubricant ointmentAlcon
Heat pack - HotHands handwarmersHeatmax Inc
Introcan Certo IV catheterB Braun425130024G x 3/4″
Aquagel Lubricating jellyLocal pharmacy
 Poly-L-lysine solution, 0.01%,SigmaP4707
cOmplete, Mini, EDTA-free Protease Inhibitor CocktailRoche4693159001
Quantichrom Creatinine Assay KitBioAssay SystemsDICT-50 
Fluorescent dye - VivoTrack 680Perkin ElmerNEV12000 
RNAlater-ICE Frozen Tissue Transition SolutionAmbion4427575
NameCompanyCatalog numberComments
Equipment and Software
7500 Realtime PCR SystemApplied Biosystems
7500 Software v2.3Applied Biosystems
Metabolic CageTecniplast Vertical type rack for 12 cages
BD FACSCanto I system BD Biosciences
BD FACSDiva software v7BD Biosciences
IVIS SpectrumCT in vivo imaging system Caliper Life Sciences 
Living Image Software v3.1Caliper Life Sciences 
Vevo 2100 imaging system VisualSonics 

References

  1. Gunther, J. H., et al. Optimizing syngeneic orthotopic murine bladder cancer (MB49). Cancer Res. 59, 2834-2837 (1999).
  2. Dobek, G. L., Godbey, W. T. An orthotopic model of murine bladder cancer. Journal of visualiz....

Explore More Articles

OrthotopicBladder TumorMurine ModelTumor DetectionIntravesical TherapyMB49 PSA CellsCatheter ImplantationUrinary PSANon muscle invasive Bladder Cancer

This article has been published

Video Coming Soon

JoVE Logo

Privacy

Terms of Use

Policies

Research

Education

ABOUT JoVE

Copyright © 2025 MyJoVE Corporation. All rights reserved